Talis Biomedical (TLIS) Stock Price, News & Analysis

Company Overview

Talis Biomedical Corporation operates as a molecular diagnostic company, focusing on developing medical devices for infectious diseases and other conditions at the point of care in the United States. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Chicago, Illinois.

Key Stats

• Today's Range: $1.43 to $1.43
• 50-Day Range: $1.40 to $1.75
• 52-Week Range: $1.04 to $9.35
• Volume: 15 shs
• Average Volume: 2,744 shs
• Market Capitalization: $2.61 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Talis Biomedical Stock Analysis - MarketRank™

Talis Biomedical scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Talis Biomedical.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Talis Biomedical is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Talis Biomedical is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Talis Biomedical has a P/B Ratio of 0.04. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.55% of the float of Talis Biomedical has been sold short.

Short Interest Ratio / Days to Cover

Talis Biomedical has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Talis Biomedical does not currently pay a dividend.

Dividend Growth

Talis Biomedical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.55% of the float of Talis Biomedical has been sold short.

Short Interest Ratio / Days to Cover

Talis Biomedical has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.

Change versus previous month

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Talis Biomedical this week, compared to 0 articles on an average week.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Talis Biomedical insiders have not sold or bought any company stock.

Percentage Held by Insiders

46.00% of the stock of Talis Biomedical is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

43.77% of the stock of Talis Biomedical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TLIS Stock Analysis - Frequently Asked Questions

How have TLIS shares performed this year?

Talis Biomedical's stock was trading at $1.7590 at the beginning of the year. Since then, TLIS shares have decreased by 18.7% and is now trading at $1.43.
View the best growth stocks for 2025 here.

How were Talis Biomedical's earnings last quarter?

Talis Biomedical Co. (NASDAQ:TLIS) posted its earnings results on Tuesday, March, 15th. The company reported ($18.90) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($19.20) by $0.30.

When did Talis Biomedical's stock split?

Talis Biomedical's stock reverse split before market open on Thursday, July 6th 2023.The 1-15 reverse split was announced on Thursday, July 6th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 6th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did Talis Biomedical IPO?

Talis Biomedical (TLIS) raised $150 million in an IPO on Friday, February 12th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, BofA Securities and Piper Sandler acted as the underwriters for the IPO and BTIG was co-manager.

How do I buy shares of Talis Biomedical?

Shares of TLIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Talis Biomedical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Talis Biomedical investors own include Bloom Energy (BE), SoFi Technologies (SOFI), Athenex (ATNX), Alkaline Water (WTER), Milestone Scientific (MLSS), TherapeuticsMD (TXMD) and Affirm (AFRM).

Company Calendar

• Last Earnings: 3/15/2022
• Today: 6/26/2025
• Next Earnings (Estimated): 8/18/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Analytical instruments
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NASDAQ:TLIS
• CIK: 1584751
• Web: talis.bio
• Phone: 650-433-3000
• Fax: N/A
• Employees: 260
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($28.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$62.01 million
• Net Margins: N/A
• Pretax Margin: -12,506.37%
• Return on Equity: -79.74%
• Return on Assets: -57.16%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.76
• Quick Ratio: 7.76

Sales & Book Value

• Annual Sales: $300 thousand
• Price / Sales: 8.69
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $37.95 per share
• Price / Book: 0.04

Miscellaneous

• Outstanding Shares: 1,823,000
• Free Float: 984,000
• Market Cap: $2.61 million
• Optionable: No Data
• Beta: 1.30